Alacris Theranostics | GenomeWeb

Alacris Theranostics

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

Researchers plan to develop a device that supports nucleic acid sequencing and protein sequencing using plasmonic nanostructures.

Alacris' ModCell approach matches patients with appropriate therapies. 

NEW YORK (GenomeWeb News) – Alacris Theranostics today said that is has gained Illumina CSPro certification for next-generation sequencing.

NEW YORK (GenomeWeb News) – German firm Alacris Theranostics today announced a deal with GlaxoSmithKline for the application of Alacris' Modcell System for drug stratification.

ModCell uses a patient's normal genomic data as well as the genomic and transcriptomic profiles of the patient's tumor to generate object-oriented models that can be used to personalize cancer treatments.

Alacris Theranostics is using whole-genome sequence analysis to develop individualized cancer therapies while EyeSense is developing ophthalmic diagnostic systems for glucose monitoring of diabetes patients.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.